Phase I/Ii Study of Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Patients Treated by Chemotherapy (Ice) in Second Line Before Autologous Transplantation.

Hematological Oncology - United Kingdom
doi 10.1002/hon.2440_6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Real-World Effectiveness of Brentuximab Vedotin Versus Physicians’ Choice Chemotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the United Kingdom and Germany

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2017English

Prospective Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients Who Are Not Suitable for Stem Cell Transplant or Multi-Agent Chemotherapy

British Journal of Haematology
Hematology
2018English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Evita: Phase I/Ii Study of Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PSY5 Comparing Brentuximab Vedotin Overall Survival Data to Standard of Care in Patients With Relapsed/Refractory Hodgkin Lymphoma (HL) Post-Autologous Stem Cell Transplant (ASCT)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy